ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
July 30 2015 - 9:00AM
Business Wire
ACADIA to Host Conference Call and Webcast on
Thursday, August 6, 2015, at 5:00 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for
the second quarter ended June 30, 2015 on Thursday, August 6, 2015,
after the U.S. financial markets close. ACADIA's management will
host a conference call and webcast on Thursday, August 6, 2015, at
5:00 p.m. Eastern Time to discuss ACADIA’s financial results and
development programs.
The conference call may be accessed by dialing 855-638-4820 for
participants in the United States or Canada and 443-877-4067 for
international callers (reference passcode 92110444). A telephone
replay of the conference call may be accessed through August 20,
2015 by dialing 855-859-2056 for callers in the United States or
Canada and 404-537-3406 for international callers (reference
passcode 92110444). The conference call also will be webcast live
on ACADIA’s website, www.acadia-pharm.com under the investors
section and will be archived there until August 20, 2015.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by
NUPLAZID™ (pimavanserin), for which we have reported positive Phase
III trial results in Parkinson’s disease psychosis and which has
the potential to be the first drug approved in the United States
for this disorder. Pimavanserin is also in Phase II development for
Alzheimer’s disease psychosis and has successfully completed a
Phase II trial in schizophrenia. ACADIA also has clinical-stage
programs for chronic pain and glaucoma in collaboration with
Allergan, Inc. All product candidates are small molecules that
emanate from internal discoveries. ACADIA maintains a website at
www.acadia-pharm.com to which we regularly post copies of our press
releases as well as additional information and through which
interested parties can subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress and timing of ACADIA’s drug discovery and development
programs, either alone or with a partner, including clinical
trials, the benefits to be derived from ACADIA’s product
candidates, in each case including NUPLAZID (pimavanserin), and the
potential for NUPLAZID to be the first drug approved in the United
States for Parkinson’s disease psychosis. These statements are only
predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization, and collaborations with others, and the fact
that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2014 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150730005257/en/
ACADIA Pharmaceuticals Inc.Steve Davis, Interim Chief Executive
OfficerLisa Barthelemy, Director of Investor
Relations858-558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024